

# Cenobamate

Catalog No: tcsc0014686



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

913088-80-9

**Formula:**

$C_{10}H_{10}ClN_5O_2$

**Pathway:**

Neuronal Signaling;Membrane Transporter/Ion Channel;Membrane Transporter/Ion Channel

**Target:**

GABA Receptor;GABA Receptor;Sodium Channel

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 126$  mg/mL (470.73 mM)

**Alternative Names:**

YKP3089

**Observed Molecular Weight:**

267.67

**Product Description**

Cenobamate, a **sodium channel** blocker, enhances **GABAergic** transmission and has the potential to be a versatile CNS drug.

IC50 & Target: Sodium channel, GABA receptor<sup>[1]</sup>.

**In Vivo:** Cenobamate (YKP3089) protects against MES induced seizures in mice with an ED<sub>50</sub> of 9.8 mg/kg i.p., and in rats with an ED<sub>50</sub> of 1.9 mg/kg p.o. In the sc Met seizures model, Cenobamate given ip inhibited the clonic seizures in mice and rats, with ED<sub>50</sub> values of 28.5 and 13.6 mg/kg, respectively. Cenobamate is also effective against seizure induced by picrotoxin with an ED<sub>50</sub> of 34.5 mg/kg in mice. Cenobamate is effective in reducing significantly the expression of stage 5 seizures in the hippocampal kindled rat (ED<sub>50</sub>=16.4 mg/kg). Cenobamate is effective in the mouse 6 Hz psychomotor seizure model at 22, 32 and 44 mA, with ED<sub>50</sub> values of 11.0, 17.9 and 16.5 mg/kg, respectively. Cenobamate also protects against lithiumpilocarpine-induced intractable seizures in rats (ip) (ED<sub>50</sub>=7.0 mg/kg)<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!